Horizon scanning in Brazil: outputs and repercussions by Gomes, Pollyanna Teresa Cirilo et al.
1https://doi.org/10.11606/S1518-8787.2019053001439
Original ArticleRev Saude Publica. 2019;53:111
Horizon scanning in Brazil: outputs 
and repercussions
Pollyanna Teresa Cirilo GomesI,II , Verónica Elizabeth MataI , Thais Conceição BorgesI , 
Dayani GalatoII  
I Ministério da Saúde. Departamento de Gestão e Incorporação de Tecnologias em Saúde. Brasília, Distrito 
Federal (DF), Brasil
II Universidade de Brasília. Faculdade de Ceilândia. Programa de Pós-Graduação em Ciências e Tecnologias da 
Saúde. Distrito Federal (DF), Brasil
ABSTRACT
OBJECTIVE: To describe the four types of horizon scanning (HS) outputs developed by the 
National Committee for Health Technology Incorporation (CONITEC) and show their main 
repercussions on the decision-making processes of the Brazilian Ministry of Health (MH).  
METHODS: Descriptive study based on participant observation and document analysis of 
HS outputs (internal reports, alert reports, briefs and sections for CONITEC recommendation 
reports) developed between January 2014 and July 2018.  
RESULTS: Fifteen internal reports, six alert reports, two briefs and 57 HS sections were produced. 
Each output has a specific structure according to its purpose. The methodological approach 
adopted for developing HS outputs in Brazil is described by EuroScan International Network. 
The outputs had institutional and international repercussions. The activities resulted in the 
inclusion of HS as a tool for reducing health lawsuits in the legal framework of the MH. One of 
the internal reports on a high-cost drug not approved in Brazil for a rare disease was requested 
by the Health Technology Assessments Network for the Americas (RedETSA), showing the 
international relevance of the outputs. The HS sections in recommendation reports influenced 
discussions about incorporating technologies into the Unified Health System. 
CONCLUSIONS: The developed outputs have purposes ranging from helping build arguments 
for defense of the MH in cases of health judicialization to inform decision-making processes. 
In addition, HS sections in recommendation reports have grown in importance recently. 
CONITEC’s HS system has been structured, and its role as a tool to inform health managers 
has shown to be been relevant.
DESCRIPTORS: Technology Assessment, Biomedical. Technology Control, Biomedical. Health 
Sciences, Technology, and Innovation Management. Policies and Cooperation in Science, 
Technology and Innovation. Evidence-Informed Policy.
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INTRODUCTION
In the last decades, the health field has been marked by the profusion of new technologies, 
not always safe, effective or with clinical superiority over those already available. Demand 
for health services and technologies has increased exponentially, with consequences for the 
allocation of human and financial resources, as well as the logistics for the implementation 
of health services1.
Facing the challenge of defining which technologies will be enabled by health systems, the 
use of health technology assessment (HTA) is increasing in support of decision-making 
processes2. The incorporation, exclusion and alteration of technologies offered by the Unified 
Health System (SUS) are carried out with the advice of the National Committee for Health 
Technology Incorporation (CONITEC), with the application of the HTA3,4,5. 
One of the HTA phases is horizon scanning (HS), which is the systematic identification of 
new and emerging technologies with the potential to impact health, health systems and/or 
society, with the purpose of timely informing decision-makers6. New technologies are those 
in the launching phase or in the early stages of diffusion of use in the health care system. 
Emerging technologies are in phases 2 or 3 of clinical research or in the pre-market phase7. 
Several countries adopt HS as an approach to prepare their health systems for such 
technologies8–12. Discussions about the organization of a Brazilian HS system started more than 
10 years ago through the Brazilian Health Technology Assessment Network (REBRATS)13,14. 
Currently, the legal attribution of HS activities at federal level belongs to CONITEC3. 
CONITEC’s HS system is part of the International Information Network on New and 
Emerging Health Technologies (EuroScan), the largest collaboration network on new and 
emerging technologies. SUS is the main client of CONITEC’s system15,16.
In response to different information needs, CONITEC’s HS system has developed internal 
reports, alert reports, briefs and HS sections in the committee’s recommendation reports. 
The purpose of this study was to describe the main characteristics of these outputs and 
show the main repercussions generated by HS.
METHODS 
Descriptive study, based on participant observation and documentary analysis of HS 
outputs prepared under CONITEC, between January 2014 and July 2018. Data collection 
was performed by searching the CONITEC website17. HS internal reports with restricted 
access were obtained from documentary research after formal authorization from the 
Ministry of Health (MH).
The publication “A toolkit for the identification and assessment of new and emerging 
health technologies”7 was used as a theoretical framework for the description of (i) internal 
reports, (ii) alert reports, (iii) briefs and (iv) HS sections in CONITEC recommendation 
reports. The resulting implications of HS outputs were shown by describing examples of 
the repercussions of the information in the MH and in the CONITEC plenary decision-
making process.
RESULTS
The outputs were designed by applying the steps of the EuroScan toolkit7. The technologies 
addressed in the outputs were indicated by the information requester (internal reports) 
or identified by searches in the clinical trial registry database ClinicalTrials.gov; on the 
websites of health regulatory agencies in Brazil (Brazilian Health Regulatory Agency – 
ANVISA), Europe (European Medicines Agency – EMA) and the United States of America 
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(Food and Drug Administration – FDA); in addition to EuroScan and Cortellis™ databases. 
Table 1 shows the characterization of the outputs. 
The recipients of output of the study period were MH managers, CONITEC plenary, and 
society. The outputs were prepared by an internal team of three people with 0.4 full-time 
equivalent HS workload (1.0 full-time equivalent corresponds to a weekly workload of 
40-hours). Some of the outputs were designed by external partners of health technology 
assessment centers at two hospitals and one university, corresponding to 0.2 full-time 
equivalents. The outputs comprised four categories of health technologies, totaling 80 
documents (Table 2).
Between 2015 and 2016, internal reports predominated (n = 13). Between 2016 and 2018, HS 
sections in CONITEC recommendation reports were the most frequent output (Figure 1).
Table 1. Characterization of the outputs developed by CONITEC’s horizon scanning system during the analyzed period and the adopted 
steps, according to the EuroScan toolkit7.
Internal Reports Alert reports Briefs
HS Sections in CONITEC 
Recommendation Reports
Target audience MH managers Society18 
MH health professionals, 
academy and managers
CONITEC plenary
Purpose
To respond the applicant’s 
specific questions (answers to 
court demands)
To disseminate information on new and emerging technologies 
and warn against the possibility of improper diffusion of these 
technologies
To support CONITEC Plenary 
discussions and prepare health 
care system for new and 
emerging technologies
Format Printed Digital
Digital (in recommendation 
reports) and oral (in CONITEC 
meetings)
System scope
Medicines, diagnostic 
methods, software 
Medicines and medical devices Medicines
Time horizon
Technologies from phase 2 of 
clinical research; or without 
licensing with ANVISA, EMA 
or FDA; or newly approved by 
these agencies
Technologies from phase 3 of 
clinical research; or without 
licensing with ANVISA, EMA 
or FDA; or newly registered at 
these agencies
Technologies from phase 2 of 
clinical research; or without 
licensing with ANVISA, EMA 
or FDA; or newly approved by 
these agencies
Technologies from phase 3 of 
clinical research; or without 
licensing with ANVISA, EMA 
or FDA; or newly registered at 
these agencies
Identification Passive process
Filtering and 
prioritization
Performed internally. In case 
of requesting information 
about a specific technology, 
filtering and prioritization 
were not performed
Performed internally.
Application of the criteria: 
MH spending on technology 
due to judicialization; burden 
of disease; availability of 
therapeutic options for the 
clinical condition in SUS; 
relevance of topic to MH 
policymakers
Performed internally.
Application of the criteria: 
technologies from phase 2 of 
clinical research and without 
licensing for the therapeutic 
indication in ANVISA or 
recently registered in the 
country
Performed internally.
Application of the criteria: 
technologies from phase 3 of 
clinical research and without 
licensing for the therapeutic 
indication in ANVISA or 
recently registered in the 
country
Evaluation
The information provided 
depended on the applicant’s 
question. No predefined 
template was established
Predefined template18 with 
information on: analyzed 
technology, regulatory 
situation in Brazil and 
worldwide, clinical research 
data, existence of Brazilian 
Clinical Guidelines published 
for the disease, scientific 
evidence of effectiveness and 
safety, technology impact 
predictions18 
No predefined template was 
established. 
Information related to 
technology(ies), patient, 
scientific evidence of efficacy 
and safety, and impact 
prediction on patient care 
and health services were 
addressed
Predefined template with 
topics: active principle, 
mechanism of action, clinical 
trial status, regulatory data 
(designation or approval of 
use as an orphan drug and 
licensing by ANVISA, EMA 
and FDA). Efficacy and safety 
data were presented orally to 
the CONITEC plenary
Type of evaluation Rapid, brief or in-depth Brief In-depth Rapid
Dissemination
Restricted circulation to the 
information requester
CONITEC website and mailing list; wide circulation CONITEC Website
Peer review Internal and external review with expert involvement
Internal review, but subject to 
external review through public 
consultations to which reports 
are submitted 
HS: horizon scanning; CONITEC: National Committee for Health Technology Incorporation; MH: Ministry of Health; ANVISA: Brazilian Health Regulatory 
Agency; EMA: European Medicines Agency; FDA: Food and Drug Administration; SUS: Unified Health System
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The most frequent themes were related to rare diseases (n = 21), rheumatology (n = 10), 
neurology (n = 9), and oncology (n = 9). The other outputs were related to hematology, 
pneumology, cardiovascular system, infectology, endocrinology and others.
Internal reports
Internal reports aimed to support the defense of the MH in cases of drugs required by court; 
to assist in the definition of medicines to establish Partnerships for Productive Development 
(PDP); to provide information to patients, MH managers and policy makers; and support 
the development of Brazilian Clinical Guidelines (PCDT)19 (Table 3).
Two types of internal reports were produced, short and extensive16. The first ones, with 
four to six pages, covered a single technology. This approach, among the types of outputs 
developed by the HS system, was the most appropriate for delivering timely information on 
new and emerging medicines to managers, given the short time available for the preparation 
of MH judicial defenses (Table 3). Internal reports of the second type, the extensive ones, 
were in-depth reviews of one or several technologies for a given clinical indication, being 
the useful modality to support the development of clinical guidelines (Table 1).
Internal reports had restricted circulation. However, those related to familial amyloid 
polyneuropathy and homozygous familial hypercholesterolaemia were pertinent to other 
audiences. Thus, they were adapted to the brief and alert report formats, respectively.
One of the internal reports that exemplifies implications of HS activities in MH is the 
metreleptin report. In 2015, lawsuits were submitted to the MH requiring the drug for 
patients with Berardinelli-Seip syndrome, a rare disease consisting of congenital generalized 
lipodystrophy20. The drug, which has not been registered in Brazil, is a recombinant 
Table 2. Number of horizon scanning outputs of the study period as to the health technology categories 
evaluated.
Type of output Quantity per technology type addressed
Internal report
(12) Medicine
(2) Diagnostics 
(1) Software 
Alert report
(5) Medicine
(1) Medical device
Brief
(1) Medicine
(1) Medical device
HS section in recommendation reports (57) Medicine
n = 80
HS: horizon scanning
Figure 1. Number of technology horizon monitoring outputs prepared per year evaluated in the study.
0 5 15
Internal reports Alert reports Briefs HS sections
15 20 25 30 35
2014
2015
2016
2017
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analogue of the human hormone leptin and had been approved by FDA in February 2014 
for that clinical indication21. Each ampule of metreleptin costs about US$ 1,766.4022, with 
an estimated spending of over $ 4 million per year to treat patients. At that time, efficacy 
and safety data on the drug were scarce, and there was no HS study on the subject in the 
EuroScan database.
The HS internal report23 contained information on the disease, epidemiological data from 
Brazil and around the world, the description of the drug, the estimated costs of treatment 
with metreleptin, and evidence on efficacy and safety, as well as regulatory and clinical 
research situations for therapeutic indication. Despite the weak evidence in favor of the 
drug use to treat the disease, court decisions were favorable to its costing.
Subsequently, the HS report23 was shared with Argentina. The request for information was 
made through the Health Technology Assessments Network for the Americas (RedETSA). 
In Argentina, the drug was being requested for compassionate use of patients with the 
disease, which could result in high expenses, as in Brazil.
Alert reports
The purpose of alert reports was to predict the impact of new and emerging legally demanded 
technologies, as well as those that could be brought to court in the future. The recipients 
of the information were judges, patients, health professionals and managers, which was 
reflected on the use of simple language and brief extension. The alert reports included a 
technology for a therapeutic indication18.
Six alerts were produced in the period: ledispavir associated with sofosbuvir for chronic 
Hepatitis C genotype 1, eliglustate tartrate for type 1 Gaucher disease, mipomersen for 
homozygous familial hypercholesterolemia, ivacaftor for cystic fibrosis, medical device 
for severe mitral regurgitation in patients with high surgical risk, and aducanumab for 
Alzheimer’s disease (Table 1).
Briefs
Table 3. Topics covered in internal  horizon scanning reports and purposes.
Topic Purpose
Beta idursulfase for mucopolysaccharidosis type 2 (Hunter syndrome)
Judicial defense 
Mipomersen for homozygous familial hypercholesterolaemia
Eculizumab for paroxysmal nocturnal hemoglobinuria and atypical 
hemolytic uremic syndrome
Metreleptin for Berardinelli-Seip syndrome
Pompe disease
Elaboration of PCDT
Fabry’s disease
Mucopolysaccharidoses type 1 and 2
Medicines for familial amyloidotic polyneuropathy associated with 
transthyretin
Watson robot
To inform MH managers
Rapid diagnostic method of bacterial meningitis
Diagnostic method of colorectal cancer by stool DNA
Medicines for chronic hepatitis C
Severe asthma medications
Recombinant factors VIII for Haemophilia A
Research and Development 
(R&D)
Medicines for Amyotrophic Lateral Sclerosis
Preparation for patients and MH 
managers meeting
PCDT: Brazilian clinical guidelines; MH: Ministry of Health
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Briefs were intended to show potential new and emerging technologies for a health condition, 
addressing various technologies (Table 1). Two reports were produced during the study 
period: “Bioabsorbable stents in percutaneous coronary intervention” and “Drugs under 
development for treating familial amyloid polyneuropathy associated with transthyretin.” 
These briefs covered two categories of technologies, medical devices and medicines 
(Figure 1), with the main target audience being health professionals and the academy.
HS Sections in Recommendation Reports
CONITEC’s recommendation reports are official MH documents that include scientific 
evidence, economic evaluation, and budget impact assessment of health technologies 
submitted for analysis for incorporation into SUS5. HS sections had aimed to present the 
drugs that could potentially compete with the one being analyzed for incorporation into 
SUS, either by new route of administration or by representing a new therapeutic class, for 
example, to support the discussions of CONITEC5.
Pilot analyses of the technological landscape of drugs in clinical development for multiple 
sclerosis were performed during the evaluation of the demands of incorporation of 
fingolimod and teriflunomide in 2014 and 2016, respectively. The HS findings were shown 
to the CONITEC plenary, influencing the recommendation issued. Due to HS’s role in 
decision-making, this output was systematically made for each drug under review by the 
commission24 as of 2017.
Between 2017 and July 2018, 58 HS sections were prepared, an average of three sections per 
month. The total of 153 new and emerging technologies were prospected. The most frequent 
health topics were rare diseases (23%), oncology (19%) and neurology (17%). In addition to 
being included in the recommendation report, the information was presented orally to the 
plenary (Table 1) and impacted in discussions and decision-making processes.
One of these repercussions occurred in the context of the analysis to incorporate 
adalimumab, etanercept, infliximab, secukinumab and ustekinumab for moderate to 
severe psoriasis25. HS appointed 13 drugs for that clinical indication, and efficacy data 
for guselkumab, ixekizumab and brodalumab suggested superiority over adalimumab, 
etanecerpt, infliximab, and ustekinumab. 
In addition, three emerging drugs (pliclidenoson, tofacitinib and voclosporin) were 
being developed for oral administration. On the other hand, all drugs under analysis for 
incorporation were administered subcutaneously or intravenously, indicating a potential 
positive repercussion of these technologies on patients’ therapeutic compliance, if they 
were registered in the country.
The scenario of potentially more effective drugs with more convenience for the patient 
in the near future resulted in the intensification of the CONITEC plenary debate on the 
preliminary recommendation not to incorporate three of the drugs under consideration.
In 2017, institutional recognition of the key role of CONITEC’s HS system in providing 
strategic information on new and emerging technologies to the MH resulted in the legal 
inclusion of horizon scanning as an activity of the commission’s advisory department as a 
tool to reduce health lawsuits26.
DISCUSSION
This study describes HS outputs developed by the Brazilian MH in order to support the 
health technologies assessment in the context of one of the largest health systems in the 
world. The results show that the EuroScan toolkit7 has been applicable to the Brazilian 
HS system. The increase in the number of outputs produced per year shows that, over 
time, the potential of HS as a tool for collecting, synthesizing and presenting information 
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on new and emerging technologies has been adopted in the decision-making processes 
in MH.
We found that, although within the same HS system, the HS steps were not uniquely 
employed to build different outputs to provide information for specific audiences. The 
study points out a differential among Brazilian HS outputs: their close relation with the 
judicialization of health, in which technologies are required through the judiciary. This 
access mechanism has been a gateway for high cost drugs with great potential for inadequate 
diffusion and irrational use, especially of technologies not approved by ANVISA27. According 
to Douw et al.28 (2003), HS systems are intended to help streamline the adoption and diffusion 
processes of new technologies. The potential positive effect of HTA in the preparation of 
defenses in cases of health judicialization has been pointed out29.
The HS has informed the Brazilian judicial system through the arguments shown in the 
defense pieces of the MH in court and, secondarily, through alert reports and briefs. This 
is caused because these HS outputs appear among search results for technologies not 
yet approved by ANVISA on tools such as Google®, as they are disseminated through the 
CONITEC website.
The sharing of metreleptin’s internal report with Argentina, case presented in this 
study, shows that CONITEC’s HS outputs can be used by other countries dealing with 
judicialization as well as other purposes. The generation of scientific evidence was 
identified as one of the priority strategies for addressing health judicialization in Latin 
America and the Caribbean30, showing the potential use of information provided by HS 
outputs for the region.
In the study by Packer et al.9 (2015) on the structure, processes and outputs of 15 EuroScan 
members, 80% of the HS systems studied reported peer review expert involvement. Some 
of CONITEC’s HS outputs are also peer reviewed. As with most HS systems reported in this 
study, the data in this investigation indicate that there is more than one group of potential 
users of the information generated by this system.
As the Swedish agency’s HS reports, Brazilian outputs do not constitute a complete 
assessment of new or emerging technology but provide managers with early information 
about them11.
Like other EuroScan members, CONITEC’s HS team is small, consisting of three people 
involved in other activities as well. CONITEC’s HS system is part of a department that 
operates in health technology assessment activities, not constituting thus a separate 
institution, as well as other members of the international network9.
Literature on the results of HS activities is scarce9,32,33. The information provided by the HS 
sections in the recommendation reports has influenced CONITEC’s recommendations. 
This allows us to state that the system described in this study generates repercussions on 
decision making for the incorporation of technologies into SUS. 
From this perspective, the increase in the number of “HS sections in recommendation 
reports” outputs in 2017 and 2018 shows their relevance to the MH. In 75% of HS systems, 
the main purpose of the activities is to support coverage and reimbursement decisions9, 
functions similar to those in the HS sections in the recommendation reports.
An important step of the Brazilian HS system will be to carry out studies focused on specific 
diseases31 and deliver this information to the corresponding thematic areas of the MH, 
in order to indicate technologies with potential for incorporation into SUS. In the United 
Kingdom, HS activities provide the National Institute for Health and Care Excellence (NICE) 
with information on technology incorporation32.
Although CONITEC cannot proactively guide the technologies that will be analyzed 
for incorporation, the internal areas of the MH may demand these evaluations from the 
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commission4. Thus, the achievement of the step discussed in the previous paragraph may 
result in a more proactive profile of activities performed by the CONITEC’s HS system. In this 
sense, the expectation that the HS system could identify early adopting technologies that 
need to be evaluated for proper use has been partially met13.
Translating briefs and alert reports into English and Spanish and making them available 
in the EuroScan database and the CONITEC website will allow the use of information by 
institutions conducting HTA and HS activities worldwide. Other challenges for CONITEC’s 
HS system will be to show information on drug obsolescence and shortages12, as well as to 
improve the dissemination strategies of the developed outputs.
The construction of the Brazilian HS system has involved the Ministry of Health, academia 
and other stakeholders. These activities have resulted in the institutional recognition of the 
methodology as an important HTA phase to inform health managers about the best evidence 
of new and emerging technologies with the potential to have legal, ethical, organizational, 
and patient care implications.
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